Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hormone composition

a technology of hormones and compositions, applied in the field of hormone compositions, can solve the problems of endometrial hyperplasia, oral estrogen therapy is associated with metabolic side effects, and the vaginal epithelium becomes more susceptible to infection and secondary inflammation, and achieves the effect of low estrogen absorption

Inactive Publication Date: 2005-09-22
NOVO NORDISK FERNCARE A G
View PDF0 Cites 44 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The invention is a hormone composition that can be used to treat vaginal symptoms. It has several advantages over existing treatments, including being effective without causing systemic absorption, improving the vaginal mucosa, and reducing the risk of osteporosis. The composition also has a positive effect on the atrophic vaginal epithelum and increases the percentage of superficial vaginal cells. Overall, the invention can provide better relief of vaginal symptoms and improve the health of the vagina and ureter."

Problems solved by technology

Additionally, the vaginal epithelium becomes more susceptible to infection and secondary inflammation.
Oral estrogen therapy has been associated with metabolic side effects as well as breast and endometrial hyperplasia.
However, there was no pretreatment biopsy for comparison.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hormone composition
  • Hormone composition
  • Hormone composition

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0031] 58 postmenopausal women were treated with tablets containing either 10 or 25 μg 17β-estradiol. The women inserted 1 tablet intravaginally, once daily for the initial 2 weeks of the study and then twice per week (Sunday & Thursday) for the following 10 weeks. Hence, some of the women only received tablets containing 10 μg 17β-estradiol and the remaining women only received tablets containing 25 μg 17β-estradiol. The estradiol profile when administering 25 or 10 μg 17β-estradiol was similar after the first dose (zero weeks of treatment) and after the above continuous treatment with 25 or 10 μg 17β-estradiol twice weekly for 10 weeks.

example 2

[0032] Treatment of atrophic vaginitis according to the present invention with low-dose 17β-estradiol tablets results in consistent, low absorption of estradiol without accumulation.

Objectives:

[0033] The vaginal absorption of 17β-estradiol (hereinafter designated E2) was evaluated and two low doses E2 (25 μg and 10 μg) were compared in postmenopausal women with atrophic vaginitis.

Design:

[0034] In a double-blind, randomized, parallel-group study, 58 postmenopausal women were treated with either 25 or 10 μg E2 for 12 weeks. Serum E2 and follicle stimulating hormone (hereinafter designated FSH) concentrations were measured throughout the study at specified intervals. The area under the curve, maximal concentration, and time to maximal concentration were determined for serum E2 concentrations. Maturation values of vaginal mucosal cells were assessed as an indicator of changes in the condition of the vaginal mucosa in response to treatment.

Results:

[0035] For both treatment group...

example 3

[0055] Treatment according to the present invention with low-dose 17β-estradiol tablets relieves vaginal symptoms, improves urogenital atrophy (vaginal health), and increases maturation of the vaginal and urethral epithelia (mucosa) without abnormal endometrial growth.

Objectives:

[0056] Vaginal tablets containing 25 or 10 μg 17β-estradiol (herein designated E2) or placebo were evaluated and compared in postmenopausal women with atrophic vaginitis.

Methods:

[0057] In a multicenter, randomized, double-blind, placebo-controlled, parallel-group study, 230 post-menopausal women received treatment with 25 or 10 μg E2 or placebo for 12 weeks. Efficacy was measured with composite scores of vaginal symptoms (dryness, soreness, and irritation) and vaginal health (secretions, epithelial integrity, surface thickness, and pH). Vaginal and urethral cytology analyses were also performed, and the vaginal maturation value was determined. Safety assessments included endometrial biopsies.

Results:...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Twice weekly administration of an analog to a Vagifem tablet which only contains 10 μg of active material has a sufficient effect.

Description

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS [0001] This patent application is a continuation of copending U.S. patent application Ser. No. 10 / 016,858, filed Dec. 14, 2001. This patent application claims the benefit of U.S. Provisional Patent Application No. 60 / 260,182 filed Jan. 5, 2001, U.S. Provisional Patent Application 60 / 260,183 filed Jan. 5, 2001, and U.S. Provisional Patent Application 60 / 260,184 filed Jan. 5, 2001 and Danish Patent Application Nos. PA 2000 01890, filed Dec. 15, 2000, PA 2000 01891, filed Dec. 15, 2000, and PA 2000 01892, filed Dec. 15, 2000. [0002] The present invention relates to a composition containing oestrogen, which is to be administered vaginally.BACKGROUND OF THIS INVENTION [0003] Vaginal atrophy can occur in postmenopausal woman and estrogen deprived women who actually do not need any systemic hormone replacement therapy but just local therapy. Consequently, local, topical treatment is preferred in order to avoid the systemic side effects due to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/56
CPCA61K31/56
Inventor KOCH, KARENKVORNING, INGELISE
Owner NOVO NORDISK FERNCARE A G
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com